ERR2598169
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_hindbrain
- 4
- umap1_2d
- -2.111953398
- umap2_2d
- -1.325424224
- umap1_3d
- -4.077135431
- umap2_3d
- 3.416644558
- umap3_3d
- -1.565938244
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.690
- MYC_TARGETS_V1+0.650
- G2M_CHECKPOINT+0.610
- MYC_TARGETS_V2+0.470
- MTORC1_SIGNALING+0.440
- ANDROGEN_RESPONSE+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.400
- PROTEIN_SECRETION+0.390
- ANGIOGENESIS+0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.250
- HEDGEHOG_SIGNALING-0.210
- TNFA_SIGNALING_VIA_NFKB-0.210
- MYOGENESIS-0.190
- KRAS_SIGNALING_DN-0.170
- P53_PATHWAY-0.170
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.130
- APICAL_JUNCTION-0.100
- ESTROGEN_RESPONSE_EARLY-0.070
- INTERFERON_GAMMA_RESPONSE-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598181 | fetal | fetal | 0.915 |
| 2 | ERR2598180 | fetal | fetal | 0.901 |
| 3 | ERR2598170 | fetal | fetal | 0.883 |
| 4 | ERR2598197 | fetal | fetal | 0.874 |
| 5 | ERR2598185 | fetal | fetal | 0.866 |
| 6 | ERR2598165 | fetal | fetal | 0.864 |
| 7 | ERR2598184 | fetal | fetal | 0.861 |
| 8 | ERR2598166 | fetal | fetal | 0.861 |
| 9 | 8ACC0F29-A39E-4C1C-A04C-ED6E5FA80C24 | — | — | 0.844 |
| 10 | MNG1179 | — | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.690 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.650 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.610 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |